HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enamelon

This article was originally published in The Rose Sheet

Executive Summary

Fluoride remineralization toothpaste to be launched in Canada in early 1999 following approval to market the dentifrice by Health Canada Therapeutic Products Directorate, Yonkers, N.Y.-based Enamelon announced Sept. 16. The OTC oral care products are formulated with soluble calcium and phosphate to fight tooth decay and "rebuild and renew tooth enamel." Enamelon's entry into Canada's $160 mil. toothpaste market is the company's "important first step in establishing an international business for Enamelon," the company said. Final distribution agreements with a Canadian distributor are expected to take place by the end of September

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel